The bigger, the better? When multicenter clinical trials and meta-analyses do not work

References

• Haines SJ, Walters BC. What is metanalysis? Surg Neurol. 1995;44(6):581–582.
   PubMedGoogle Scholar
• Messerer D, Porzsolt F, Hasford J, et al. [Advantages and problems of multicenter therapy studies exemplified by a study of the treatment of metastasizing renal cell carcinoma with recombinant interferon-alpha-2c] . Onkologie. 1987;10(1):43–49.
   PubMedGoogle Scholar
• Llaurado JG. Metanalysis: a new scientific endeavor. Int J Biomed Comput. 1988;22(2):77–79.
   PubMedGoogle Scholar
• Jobst B. The art of switching antiepileptic medications: keep trying or just let it be. Epilepsy Curr. 2013;13(2):76–77.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang LL, Shang D, et al. Gene polymorphism of DNA repair gene X-ray repair cross complementing group 1 and xeroderma pigmentosum group D and environment interaction in non-small-cell lung cancer for Chinese nonsmoking female patients. Kaohsiung J Med Sci. 2019;35(1):39–48.
   PubMed Web of Science ®Google Scholar
• Elwan N, Assal F, Elfert A, et al. Genetic susceptibility in family members of Egyptian Hepatitis C virus infected patients: role of interleukin-12 B gene polymorphism. Infect Disord Drug Targets. 2019;19(1):81–87.
   PubMedGoogle Scholar
• Friedman LS, Szabo CI, Ostermeyer EA, et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet. 1995;57(6):1284–1297.
   PubMed Web of Science ®Google Scholar
• Francis J, Zvada SP, Denti P, et al. A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine. Antimicrob Agents Chemother. 2019;63(4):e01964–18.
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997;60(5):1059–1067.
   PubMed Web of Science ®Google Scholar
• Bahar AY, Taylor PJ, Andrews L, et al. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. Cancer. 2001;92(2):440–445.
   PubMed Web of Science ®Google Scholar
• Tung N, Garber JE, Lincoln A, et al. Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations. J Clin Oncol. 2012;30(35):4447–4448.
   PubMed Web of Science ®Google Scholar
• Walsh T, Mandell JB, Norquist BM, et al. Genetic predisposition to breast cancer due to mutations other than BRCA1 and BRCA2 founder alleles among Ashkenazi Jewish women. JAMA Oncol. 2017;3(12):1647–1653.
   PubMed Web of Science ®Google Scholar
• Check Hayden E. The rise and fall and rise again of 23andMe. Nature. 2017;550(7675):174–177.
   PubMed Web of Science ®Google Scholar
• Stoekle HC, Mamzer-Bruneel MF, Vogt G, et al. 23andMe: a new two-sided data-banking market model. BMC Med Ethics. 2016;17:19.
   PubMed Web of Science ®Google Scholar
• Harari S, Madotto F, Caminati A, et al. Epidemiology of idiopathic pulmonary fibrosis in northern Italy. PloS One. 2016;11(2):e0147072.
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med. 2012;33(1):41–50.
   PubMed Web of Science ®Google Scholar
• Sauleda J, Nunez B, Sala E, et al. Idiopathic pulmonary fibrosis: epidemiology, natural history, phenotypes. Med Sci. 2018;6(4):110.
   Google Scholar
• Huang H, Peng X, Zhong C. Idiopathic pulmonary fibrosis: the current status of its epidemiology, diagnosis, and treatment in China. Intractable Rare Dis Res. 2013;2(3):88–93.
   PubMedGoogle Scholar
• Sun L, Chen Y, Wu R, et al. Changes in definition lead to changes in the clinical characteristics across COPD categories according to GOLD 2017: a national cross-sectional survey in China. Int J Chron Obstruct Pulmon Dis. 2017;12:3095–3102.
   PubMed Web of Science ®Google Scholar
• Vestbo J. COPD: definition and phenotypes. Clin Chest Med. 2014;35(1):1–6.
   PubMed Web of Science ®Google Scholar
• Petsonk EL, Hnizdo E, Attfield M. Definition of COPD GOLD stage I. Thorax. 2007;62:1107–1108.
   PubMed Web of Science ®Google Scholar
• Perez-Padilla R, Wehrmeister FC, Montes de Oca M, et al. Instability in the COPD diagnosis upon repeat testing vary with the definition of COPD. PloS One. 2015;10(3):e0121832.
   PubMed Web of Science ®Google Scholar
• Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48(3):664–673.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–357.
   PubMed Web of Science ®Google Scholar
• Calles-Escandon J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33(4):721–727.
   PubMed Web of Science ®Google Scholar
• Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Dia Care. 2014;37(3):634–643.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Margolis KL, Sellmeyer DE, et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care. 2012;35(7):1525–1531.
   PubMed Web of Science ®Google Scholar
• Najman DM. Intensive therapy of type 2 diabetes (ACCORD trial) (OCTOBER 2008. CCJM. 2009;76(2):83.1–4.
   Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med. 2008;358:2545–2559.
   PubMed Web of Science ®Google Scholar
• Braffett BH, Dagogo-Jack S, Bebu I, et al. Association of insulin dose, cardiometabolic risk factors, and cardiovascular disease in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study. Diabetes Care. 2019;42(4):657–664.
   PubMed Web of Science ®Google Scholar
• Writing Group for the DERG. Coprogression of cardiovascular risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study. Diabetes Care. 2016;39:1621–1630.
   PubMed Web of Science ®Google Scholar
• Diabetes C. Complications trial/epidemiology of diabetes I and complications study research G. intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016;39:686–693.
   PubMed Web of Science ®Google Scholar
• Gubitosi-Klug RA, Braffett BH, White NH, et al. Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT/EDIC study. Diabetes Care. 2017;40(8):1010–1016.
   PubMed Web of Science ®Google Scholar
• Vogt H, Hofmann B, Getz L. Personalized medicine: evidence of normativity in its quantitative definition of health. Theor Med Bioeth. 2016;37(5):401–416.
   PubMed Web of Science ®Google Scholar
• Suwinski P, Ong C, Ling MHT, et al. Advancing personalized medicine through the application of whole exome sequencing and big data analytics. Front Genet. 2019;10:49.
   PubMed Web of Science ®Google Scholar
• El-Alti L, Sandman L, Munthe C. Person centered care and personalized medicine: irreconcilable opposites or potential companions? Health Care Anal. 2019;27(1):45–59.
   PubMed Web of Science ®Google Scholar
• Eyerich K, Tuting T. [Personalized medicine]. Hautarzt. 2019;70(1):4
   PubMed Web of Science ®Google Scholar
• Jorgensen JT. twenty years with personalized medicine: past, present, and future of individualized pharmacotherapy. The Oncologist. 2019;24(7):e432–e440.
   PubMed Web of Science ®Google Scholar
• Walker E, Hernandez AV, Kattan MW. Meta-analysis: its strengths and limitations. Cleve Clin J Med. 2008;75(6):431–439.
   PubMed Web of Science ®Google Scholar
• Stevens RD, Wu CL. Strengths and limitations of meta-analysis. J Cardiothorac Vasc Anesth. 2007;21(1):1–2.
   PubMed Web of Science ®Google Scholar
• Flather MD, Farkouh ME, Pogue JM, et al. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials. 1997;18(6):568–579.
   PubMedGoogle Scholar
• Cheng A, Kessler D, Mackinnon R, et al. Conducting multicenter research in healthcare simulation: lessons learned from the INSPIRE network. Adv Simul (Lond). 2017;2:6.
   PubMedGoogle Scholar